Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Senaparib ± bevacizumab as first-line maintenance in advanced HR-proficient ovarian cancer
ChiCTR2600117644Phase 4Not yet recruiting
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of senaparib and bevacizumab in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Guangdong Provincial People's Hospital. Primary endpoint: Progression-Free Survival. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
senaparibbevacizumab
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ChiCTR2600117644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600117644.